HKSE - Delayed Quote HKD

CARsgen Therapeutics Holdings Limited (2171.HK)

5.450

+0.120

(+2.25%)

At close: 4:08 PM GMT+8

CARsgen Announced 2023 Annual Results

March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results.

PR Newswire 30 days ago
$NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma$
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration ("NMPA") of China has approved the New Drug Application ("NDA") for zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product candidate against BCMA), for the treatment of adult patients with relapsed or refractory multiple myeloma who have p

PR Newswire last month
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ("ASCO GI"), the Company presented a poster with study results for satricabtagene autoleucel ("satri-cel", R&D code: CT041, an autologous CAR-T product candidate against Claudin18.2), which include the dose escalation resu

PR Newswire 3 months ago
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypican-3 (GPC3), has achieved Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for patients with GPC3-positive stage IIIa hepatocellular carcinoma who are at high risk of recurrence after surgical r

PR Newswire 3 months ago
CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual Meeting, the Company presented one poster with study results for zevorcabtagene autoleucel ("zevor-cel", R&D code: CT053, an autologous CAR T-cell therapy candidate against BCMA), which include the 3-year follow-up on efficacy and safety results fro

PR Newswire 4 months ago
$CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia$
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for CT071, an autologous CAR T-cell therapy candidate targeting G protein-coupled receptor class C group 5 member D (GPRC5D), for the treatment of patients with relapsed/refractory multiple myeloma (MM) or rela

PR Newswire 4 months ago
CARsgen Announces Formation of its Clinical Advisory Board

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board. This highly regarded panel of experts will provide invaluable guidance and insights for the global clinical development of company's innovative product candidates.

PR Newswire 5 months ago
CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen's innovative CAR-GPC3 T-cell therapy. These results were recently published in Cancer Communications as the cover story, titled "Combined local therapy and CAR-GPC3 T-cell the

PR Newswire 6 months ago
Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of the treatment of metastatic pancreatic cancer with CARsgen's CT041, an innovative Claudin (CLDN) 18.2 CAR T-cell Therapy, in Journal of Hematology & Oncology (IF 23.186), titled "CT041 CAR T cell therapy for Claudin18.2–positive metastatic pancreatic cancer" (https://jhoonline.bi

PR Newswire 7 months ago
CARsgen Announced 2023 Interim Results

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results.

PR Newswire 8 months ago
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S., for the treatment of CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.

PR Newswire 11 months ago
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche's PD-L1 checkpoint inhibitor, along with chemotherapy (capecitabine and oxaliplatin) achieved IND clearance from the CDE for first-line treatment Claudin18.2 (CLDN18.2) positive unresectable locally advanced, recurrent or metastatic gastric

PR Newswire 11 months ago

Performance Overview

Return	2171.HK	HANG SENG INDEX
YTD	-16.15%	+3.54%
1-Year	-55.62%	-10.03%
3-Year	--	-38.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CARsgen Therapeutics Holdings Limited (2171.HK)

CARsgen Announced 2023 Annual Results

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

CARsgen Announces Formation of its Clinical Advisory Board

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology

CARsgen Announced 2023 Interim Results

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

Performance Overview